Sobi Ramps Up In Rare Diseases With Apellis Deal
$250m Upfront Fee For Rights To Pegcetacoplan
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
